Full history for every metric is available with a Kvantra account
Cara Therapeutics, Inc. (CARA)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 135 | 23 | 42 | 21 | 7 | 0 | -3 |
| Operating profit | $m | -27 | -32 | |||||
| Net profit | $m | 8 | -88 | -83 | -119 | -71 | -18 | -31 |
| EPS reported | $ | -3.26 | -3.36 | |||||
| Operating cashflow per share | $ | -0.00 | -0.00 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.00 | -0.00 | |||||
| Free cash flow | $m | -23 | -25 | |||||
| Net debt | $m | -31 | -16 | |||||
| Book value equity | $m | 21 | 8 | |||||
| Book value per share | $ | 0.00 | 0.00 | |||||
| Number of shares | m | 7,783.18 | 9,381.34 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 5,653.02 | 0.97 | |||||
| P/S LTM | x | 0.00 | -3.16 | |||||
| P/FCF LTM | x | -5,038.86 | -0.32 | |||||
| EV/EBITDA LTM | x | 1,246,185.94 | 0.71 | |||||
| EV/Sales LTM | x | 0.00 | 2.98 | |||||
| Earnings Yield LTM | % | -0.02% | -0.06% | |||||
| FCF Yield | % | -0.02% | -308.60% | |||||
| Quality | ||||||||
| ROE | % | -86.96% | -171.47% | |||||
| ROIC | % | -126.49% | -370.11% | |||||
| Operating margin | % | 0.00% | 1228.5% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | 974.27% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -116.91 | -172.61 | |||||
| Net Debt/EBITDA | x | -216.14 | 1.46 | |||||
| EBIT/Net interest | x | 0.00 | 11.01 | |||||
| Net debt/market cap | % | -0.03% | -194.38% | |||||
| Net debt/Equity | x | -1.46 | -1.88 | |||||
| Gross debt/equity | x | 0.01 | 0.02 | |||||
Company overview
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline includes potential medicines designed to interact with the body's peripheral nervous system and immune cells. KORSUVA (difelikefalin), an injectable formulation, stands as their flagship product. It is approved for treating moderate-to-severe pruritus linked to chronic kidney disease in adult patients undergoing hemodialysis. Additionally, Cara Therapeutics is advancing an oral version of KORSUVA (difelikefalin) through its pipeline. This oral candidate has successfully completed Phase II clinical trials for relieving pruritus associated with atopic dermatitis and chronic kidney disease not requiring dialysis (NDD-CKD). It is also currently undergoing Phase II evaluation for pruritus related to chronic liver disease (specifically primary biliary cholangitis) and for notalgia paresthetica. The company has established international licensing agreements: one with Maruishi Pharmaceutical Co., Ltd for the development, production, and commercialization of difelikefalin-containing products targeting acute pain and uremic pruritus in Japan, and another with Chong Kun Dang Pharmaceutical Corporation for similar activities concerning difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Cara Therapeutics, Inc. (CARA)
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline includes potential medicines designed to interact with the body's peripheral nervous system and immune cells. KORSUVA (difelikefalin), an injectable formulation, stands as their flagship product. It is approved for treating moderate-to-severe pruritus linked to chronic kidney disease in adult patients undergoing hemodialysis. Additionally, Cara Therapeutics is advancing an oral version of KORSUVA (difelikefalin) through its pipeline. This oral candidate has successfully completed Phase II clinical trials for relieving pruritus associated with atopic dermatitis and chronic kidney disease not requiring dialysis (NDD-CKD). It is also currently undergoing Phase II evaluation for pruritus related to chronic liver disease (specifically primary biliary cholangitis) and for notalgia paresthetica. The company has established international licensing agreements: one with Maruishi Pharmaceutical Co., Ltd for the development, production, and commercialization of difelikefalin-containing products targeting acute pain and uremic pruritus in Japan, and another with Chong Kun Dang Pharmaceutical Corporation for similar activities concerning difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free